Becton, Dickinson and Company

BDX Healthcare Medical Instruments & Supplies

Becton, Dickinson and Company’s revenue for fiscal 2025 (year ended September 2025) was $21.8 billion, up 8.24% from fiscal 2024.

Revenue
−9.55%
EPS
−31.5%
Free cash flow
−31.6%
Total debt
−22.9%

Quarter to June 2026, against a year earlier

212.83 0.72 −0.34%
Market cap
$58.2B
P/E
64.1×
Fwd P/E
39.2×
Dividend yield
1.87%
F-score
7/9
Altman Z
1.85
Beneish M
−2.64
Dividend safety
67/100
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
3.77% 4.61% 6.96% 6.54%

+8 more TTM periods

Piotroski F-Score
7 7 7 7
ROA
1.78% 2.16% 3.21% 2.98%
ROIC
3.89% 3.94% 4.06% 3.82%
Return on Tangible Assets
19.53% 20.37% 23.74% 22.91%
Average Days of Receivables
41.40 37.67 41.75 40.04
Free Cash Flow per Share
11.66 12.45 9.21 9.28
Free Cash Flow
3,203.00 3,495.00 2,631.00 2,670.00
Other line items

Show all line items

Columns are period end dates · fundamentals updated 26 Oct 2026